middle.news
Why Did Mayne Pharma Keep the FDA Letter Under Wraps Amid Acquisition?
1:55am on Monday 2nd of June, 2025 AEST
•
Pharmaceuticals
Read Story
Why Did Mayne Pharma Keep the FDA Letter Under Wraps Amid Acquisition?
1:55am on Monday 2nd of June, 2025 AEST
Key Points
FDA Untitled Letter related to NEXTSTELLIS shared confidentially with scheme bidder
Mayne Pharma deems letter not materially price sensitive, no market disclosure required
Company confirms compliance with ASX Listing Rule 3.1 and continuous disclosure policy
Share price volatility followed public release of FDA letter
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mayne Pharma (ASX:MYX)
OPEN ARTICLE